Arena Defends Obesity Drug After Phase III BLOOM Wilts
This article was originally published in Pharmaceutical Approvals Monthly
Arena is playing up the robust safety profile and approvability of its obesity drug lorcaserin after unveiling lackluster efficacy results from the Phase III BLOOM trial
You may also be interested in...
Firm stresses Phase III efficacy results will pass muster with FDA.
CEO hails positive Phase III data, but not all analysts are convinced.
A stipulation that patients should fail lifestyle modifications before they are eligible to enroll in clinical trials for obesity drugs needs to be modified, according to industry comments on an FDA draft guidance on development of weight management drugs